Mannkind Corp.'s director, Steven B. Binder, engaged in notable transactions involving the sale of the company's common stock over two recent dates. On May 12, 2026, Mr. Binder sold a total of 16,940 shares of Mannkind’s common stock. The aggregated value of these specific sales amounted to approximately $55,732. During this transaction, the weighted average price at which the shares were sold was determined to be $3.29 per share. Details regarding individual sales prices revealed a range spanning from $3.25 to $3.34.
It is important to note that this initial sale of stock was executed under the framework of a Rule 10b5-1 trading plan, a mechanism that Mr. Binder had established on December 2, 2025. This structured approach governs how and when the transactions take place.
The reported selling activity occurred while Mannkind shares faced recent market weakness, having declined by approximately 44% year-to-date, with the stock trading at $3.21 per share. Despite this observed downturn in share price, external analysis from InvestingPro suggests that the stock may remain undervalued when compared to its determined Fair Value.
A subsequent transaction was reported on May 11, 2026. On this date, Mr. Binder disposed of an additional 5,560 shares of Mannkind common stock. These particular shares were valued at roughly $19,571, based on a price of $3.52 per share. The purpose for disposing of these specific shares was to cover tax withholding obligations that arose from the vesting of Restricted Stock Units (RSUs) originally granted to him on May 10, 2022.
Following both transactions, Mr. Binder's direct holding in Mannkind Corp. common stock stands at 808,008 shares. For investors seeking deeper insights into the financial health and valuation of Mannkind, comprehensive analysis is available through InvestingPro. This platform provides additional ProTips and detailed metrics concerning the company.
Beyond insider activity, MannKind Corporation recently published its first-quarter 2026 earnings report. The results indicated a 15% year-over-year increase in revenue, reaching $90 million. Crucially, this revenue growth was largely attributed to the inclusion of FUROSCIX revenues following the acquisition of scPharmaceuticals. This highlights an active integration effort designed to expand the company's revenue base.
Despite the positive development in top-line revenue figures, the company recorded a non-GAAP net loss of $0.02 per share. This reported loss did not align with the previously forecasted loss of $0.01 per share. These combined financial results underscore Mannkind's continuous efforts to incorporate newly acquired entities into its core revenue stream and operational structure. While market reactions to these earnings were noted, specific stock price movements resulting from this report are not detailed in this analysis.
Overall, the recent activities undertaken by MannKind reflect a strategic focus aimed at enhancing financial performance through expanding product offerings and integrating new business units, demonstrating an ongoing commitment to growth despite current market fluctuations and reported net losses.